Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers

Shiroh Matsukura, Kohji Miyazaki, Hiroyuki Yakushiji, Akiomi Ogawa, Katsumi Harimaya, Yusaku Nakabeppu, Mutsuo Sekiguchi

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: O6-Methylguanine-DNA methyltransferase (MGMT) is an enzyme that repairs O6-methylguanine, a promutagenic DNA base damaged by endogenous and environmental alkylating agents. There are few reports that describe whether or not abnormal MGMT expression correlates with the prognosis in human solid cancers. Methods: The expression of MGMT was immunohistochemically evaluated in 60, 62, 105, and 46 paraffin-embedded samples from patients with curatively resected hepatocellular, gastric, colorectal, and breast cancers, respectively. Results: The expression of MGMT was a positive predictive factor for overall survival in hepatocellular (P = .005) and gastric cancers (P < .001) and for relapse-free survival in breast cancers (P < .001). MGMT-positive gastric tumors (n = 42) were correlated with the absence of serosal invasion (P = .045), lymph node metastasis (P = .006), intestinal type (P = .018), and low pathological tumor, node, metastasis stage (P < .001). All breast tumors that recurred locally after operation were MGMT negative (P = .004). The clinicopathologic characteristics of colorectal cancers with respect to MGMT expression did not significantly differ. Conclusions: The expression of MGMT is a predictive prognostic marker in patients with hepatocellular, gastric, and breast cancers. These findings may help to establish therapeutic strategies for patients with these types of solid cancer.

Original languageEnglish
Pages (from-to)807-816
Number of pages10
JournalAnnals of Surgical Oncology
Volume8
Issue number10
DOIs
Publication statusPublished - Dec 1 2001

Fingerprint

Methyltransferases
Liver Neoplasms
Stomach Neoplasms
Breast Neoplasms
DNA
Colorectal Neoplasms
Neoplasms
Neoplasm Metastasis
O-(6)-methylguanine
Survival
Alkylating Agents
Paraffin
Stomach
Lymph Nodes
Recurrence
Enzymes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers. / Matsukura, Shiroh; Miyazaki, Kohji; Yakushiji, Hiroyuki; Ogawa, Akiomi; Harimaya, Katsumi; Nakabeppu, Yusaku; Sekiguchi, Mutsuo.

In: Annals of Surgical Oncology, Vol. 8, No. 10, 01.12.2001, p. 807-816.

Research output: Contribution to journalArticle

Matsukura, Shiroh ; Miyazaki, Kohji ; Yakushiji, Hiroyuki ; Ogawa, Akiomi ; Harimaya, Katsumi ; Nakabeppu, Yusaku ; Sekiguchi, Mutsuo. / Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers. In: Annals of Surgical Oncology. 2001 ; Vol. 8, No. 10. pp. 807-816.
@article{cacd538dd29545c58024ab4900e7633b,
title = "Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers",
abstract = "Background: O6-Methylguanine-DNA methyltransferase (MGMT) is an enzyme that repairs O6-methylguanine, a promutagenic DNA base damaged by endogenous and environmental alkylating agents. There are few reports that describe whether or not abnormal MGMT expression correlates with the prognosis in human solid cancers. Methods: The expression of MGMT was immunohistochemically evaluated in 60, 62, 105, and 46 paraffin-embedded samples from patients with curatively resected hepatocellular, gastric, colorectal, and breast cancers, respectively. Results: The expression of MGMT was a positive predictive factor for overall survival in hepatocellular (P = .005) and gastric cancers (P < .001) and for relapse-free survival in breast cancers (P < .001). MGMT-positive gastric tumors (n = 42) were correlated with the absence of serosal invasion (P = .045), lymph node metastasis (P = .006), intestinal type (P = .018), and low pathological tumor, node, metastasis stage (P < .001). All breast tumors that recurred locally after operation were MGMT negative (P = .004). The clinicopathologic characteristics of colorectal cancers with respect to MGMT expression did not significantly differ. Conclusions: The expression of MGMT is a predictive prognostic marker in patients with hepatocellular, gastric, and breast cancers. These findings may help to establish therapeutic strategies for patients with these types of solid cancer.",
author = "Shiroh Matsukura and Kohji Miyazaki and Hiroyuki Yakushiji and Akiomi Ogawa and Katsumi Harimaya and Yusaku Nakabeppu and Mutsuo Sekiguchi",
year = "2001",
month = "12",
day = "1",
doi = "10.1245/aso.2001.8.10.807",
language = "English",
volume = "8",
pages = "807--816",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers

AU - Matsukura, Shiroh

AU - Miyazaki, Kohji

AU - Yakushiji, Hiroyuki

AU - Ogawa, Akiomi

AU - Harimaya, Katsumi

AU - Nakabeppu, Yusaku

AU - Sekiguchi, Mutsuo

PY - 2001/12/1

Y1 - 2001/12/1

N2 - Background: O6-Methylguanine-DNA methyltransferase (MGMT) is an enzyme that repairs O6-methylguanine, a promutagenic DNA base damaged by endogenous and environmental alkylating agents. There are few reports that describe whether or not abnormal MGMT expression correlates with the prognosis in human solid cancers. Methods: The expression of MGMT was immunohistochemically evaluated in 60, 62, 105, and 46 paraffin-embedded samples from patients with curatively resected hepatocellular, gastric, colorectal, and breast cancers, respectively. Results: The expression of MGMT was a positive predictive factor for overall survival in hepatocellular (P = .005) and gastric cancers (P < .001) and for relapse-free survival in breast cancers (P < .001). MGMT-positive gastric tumors (n = 42) were correlated with the absence of serosal invasion (P = .045), lymph node metastasis (P = .006), intestinal type (P = .018), and low pathological tumor, node, metastasis stage (P < .001). All breast tumors that recurred locally after operation were MGMT negative (P = .004). The clinicopathologic characteristics of colorectal cancers with respect to MGMT expression did not significantly differ. Conclusions: The expression of MGMT is a predictive prognostic marker in patients with hepatocellular, gastric, and breast cancers. These findings may help to establish therapeutic strategies for patients with these types of solid cancer.

AB - Background: O6-Methylguanine-DNA methyltransferase (MGMT) is an enzyme that repairs O6-methylguanine, a promutagenic DNA base damaged by endogenous and environmental alkylating agents. There are few reports that describe whether or not abnormal MGMT expression correlates with the prognosis in human solid cancers. Methods: The expression of MGMT was immunohistochemically evaluated in 60, 62, 105, and 46 paraffin-embedded samples from patients with curatively resected hepatocellular, gastric, colorectal, and breast cancers, respectively. Results: The expression of MGMT was a positive predictive factor for overall survival in hepatocellular (P = .005) and gastric cancers (P < .001) and for relapse-free survival in breast cancers (P < .001). MGMT-positive gastric tumors (n = 42) were correlated with the absence of serosal invasion (P = .045), lymph node metastasis (P = .006), intestinal type (P = .018), and low pathological tumor, node, metastasis stage (P < .001). All breast tumors that recurred locally after operation were MGMT negative (P = .004). The clinicopathologic characteristics of colorectal cancers with respect to MGMT expression did not significantly differ. Conclusions: The expression of MGMT is a predictive prognostic marker in patients with hepatocellular, gastric, and breast cancers. These findings may help to establish therapeutic strategies for patients with these types of solid cancer.

UR - http://www.scopus.com/inward/record.url?scp=0035665415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035665415&partnerID=8YFLogxK

U2 - 10.1245/aso.2001.8.10.807

DO - 10.1245/aso.2001.8.10.807

M3 - Article

VL - 8

SP - 807

EP - 816

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -